Brind.

Benzinga reports on market expectations for Amgen, Pfizer, and Gilead Sciences.

2 reports, 1 independent Updated Aug 4

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Benzinga reports on market expectations for Amgen, Pfizer, and Gilead Sciences.

Who's involved

What this event is mainly about

Amgen Pfizer Gilead Sciences

Keep exploring

The entities involved

Amgen
American multinational biopharmaceutical company
- MSKCC director Rudin presented trial data involving Amgen on October 25, 2026.Sun 17:06
- Amgen and Gilead Sciences are two companies that compete within the biotech industry.Sun 11:22
Pfizer
American multinational pharmaceutical and biotechnology corporation
- A trial involving Pfizer CEO Albert Bourla and Bill Gates was held in Leeuwarden, with Peter Stassen speaking in court.Sun 23:12
- MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Sat 22:36
Gilead Sciences
American company
- Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.Fri 16:08
- Gilead Sciences supplied sacituzumab govitecan for a clinical trial on October 22, 2026.Thu 12:56

Related events

Benzinga generated content regarding the financial performance of Gilead Sciences on June 17, 2026.Jun 18

Coverage

Newest first; wire copies grouped

Aug 4benzinga.com
Aug 3benzinga.com